Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins Lund, Sweden, November 15, 2023: Gedea Biotech today announced that it has raised 1.5 MEUR (16,5 MSEK) to initiate and accelerate clinical trial activities supporting pHyph™ applicable for antibiotic free treatment of vaginal infections.…

This pivotal study aims to confirm the safety and efficacy of pHyph in treating and preventing BV recurrence Patient recruitment will now be initiated and 5 Swedish clinics are planned to attend Previous studies in BV have demonstrated pHyph to have a BV cure rate in line with antibiotics on…

Further strengthens Gedea Biotech’s broad patent portfolio pHyph has demonstrated a superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Additionally, unlike antibiotics, pHyph will not promote antimicrobial resistance Lund, Sweden, September 13, 2023. Swedish women’s health company Gedea Biotech announced today that…

Gedea Biotech has developed the world’s first antibiotic-free treatment to both treat and prevent bacterial vaginosis. The treatment is called pHyph, and is a vaginal tablet that has shown a medical effectiveness in treating bacterial vaginosis in line with antibiotics on the market, but with a superior safety profile and…

Lund, Sweden, May 24, 2023: Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for: An ongoing proof-of-concept study for the treatment of Vulvo Vaginal Candidiasis (VVC)…

Up to 75% of all women are affected by vaginal infection in their lifes Self-diagnoses leads often to unnecessary and inappropriate treatment use This study aims to confirm the safety and efficacy of pHyph in VVC Lund, Sweden, May 2, 2023. Gedea Biotech today announces that the treatment of the…

Important expansion of patent estate in the largest market for vaginal bacterial infections pHyph has shown superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate

Lund, Sweden April 12, 2023: Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the approved certification are important milestones for achieving CE marking for pHyph, the company’s antibiotic-free treatment for bacterial vaginosis.

Impact on microbiome could be key to preventing vulvovaginal infection recurrence Lund, Sweden, April 4, 2023: Gedea Biotech today announced it has been awarded SEK 3M grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge hospital and Karolinska Institute, to fund a further…

News The results from the NEFERTITI-study have received much attention since they were first published in a press release from October 11th. During the last week of November, there were no less than three publications that mentioned Gedea and were spread through e.g., Twitter and LinkedIn. First out was Biose…

Uppdated 2022-11-14- Symptom reduction was seen in 90% of patients and absence of symptoms was noted in 70% of patients- Clinical cure rate was 50,4% in the pHyph group, which is in line with many antibiotic treatments on the market- The rate of recurrence of BV was substantially lower at…

  PRESS RELEASEGedea Biotech today announces that it has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will start the EpHect clinical study of its lead product, pHyph, a vaginal tablet for topical treatment. The open-labelled study is designed to confirm the safety and…

PRESS RELEASEGedea Biotech has been awarded the prestigious award "Rapidus Company of the Year". The ceremony was held at Rapidus annual "birthday party", Thursday April 28th. This title has been awarded annually since 2001 and companies such as Cellavision, FlatFrog, QlikTech and Camurus have all been awarded. Rapidus awards companies that are the “Big Industries” of the future, i.e. small companies with potential, according…

PRESS RELEASE Lund, Sweden, February 08, 2022. Swedish women’s health company Gedea Biotech today announced that despite the COVID-19 pandemic it has successfully completed recruitment of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind…

Labiotech.eu is the leading online media for the biotech industry in Europe. Gedea Biotech is the only Swedish company on Labiotech's annual list  "The 20 European Biotech Companies to Watch in 2022". Labiotech has run articles about Gedea several times, focusing on our ambition to develop a treatment that not only treats…

PRESS RELEASE Lund, Sweden, December 21, 2021. Swedish women’s health company Gedea Biotech today announced that it has received funding for a research project with the Centre for Translational Microbiome Research at Karolinska Institutet (KI), for its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The project…

Lund December 1, 2021. Femtech start-up Biotech today announces that Ton Berkien has been elected Chairman of the Board of Directors of Gedea Biotech. He replaces Olov Sterner, one of the founders of Gedea who continues as a board member.

PRESS RELEASE Lund, Sweden, October 25, 2021. Patent now valid in two of the world’s largest markets, Europe and USA until 2037Swedish women’s health company Gedea Biotech today announced that the company has been granted a patent from the European Patent Office, covering the treatment of fungal infections with compound glucono-δ-lactone (GDL).…

Lund, Sweden, September 8, 2021, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled more than 50% of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed…

Lund, Sweden, August 31, 2021. Swedish women’s health company Gedea Biotech today announced that it has been granted a patent (US 10,993,907) by the United States Patent and Trademark Office (USPTO) for thetreatment of fungal infections by the company’s compound glucono-δ-lactone (GDL). The patent can be kept in force until 2037.

Now, 57 patients, patients have been enrolled in the NEFERTITI clinical trial. Thanks to persistent and inventive investigators, in Sweden and in England, the study progresses at a steady pace. The NEFERTITI study examines the clinical effect of Gedea's treatment of pHyph in bacterial vaginosis, both as a treatment and…

PRESS RELEASE 2021-02-01Lund, Sweden, February 2nd, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled the first patient in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed to…

Labiotech.eu is the leading online media for the biotech industry in Europe. Gedea Biotech is the only Swedish company on Labiotech's annual list  "The 21 European Biotech Companies to Watch in 2021". Labiotech has run articles about Gedea several times, focusing on our ambition to develop a treatment that not only…

Follow-up study of Microbiome samples now underway at Karolinska to provide further insights Lund, December 16, 2020: Gedea Biotech today announced that results from a recently published study show that their pHyph antibiotic-free treatment for bacterial vaginosis has a high cure rate and prevents recurrence of the infection.

Lund, Sweden, October 27, 2020. Gedea Biotech,today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study…

Lund, Sweden, April 7, 2020. Gedea Biotech, an innovative women’s health company today received its certificate in accordance with ISO 13485: 2016 (Medical devices - Quality management system - Requirements for regulatory purposes). The scope of the certificate includes design, development,marketing, distribution and production of antibiotic-free vaginal tablets intended to…

PRESS RELEASE Lund, Sweden, March 11, 2020. Gedea Biotech, an innovative women’s health company today reported results from a clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). In this open-label, single-armed, multi-center study, 82% of the women were clinically cured after…

This year´s International Womon´s Day, Gedea wants to support UN Women´s campaign “I am Generation Equality: Realizing Women’s Rights”.The Generation Equality campaign is bringing together people of every gender, age, ethnicity, race, religion and country, to drive actions that will create the gender-equal world we all deserve.One of Gedea´s  Sustainable…

In 2019 Gedea gained good traction in media, both Swedish and international. Rapidus, BioStock, Life Science Sweden, Läkemedelsmarknaden and other Swedish business/medtech media published articles about us. American BioSpace published no less than three press items on Gedea. We are happy to now "be on their radar".   Here is…

In 2019, we conducted two clinical studies, developed the quality system, moved into new premises, received grants from SweLife and as a fantastic end to the year we could tell that we were granted 3 million Euro by the EU Horizon 2020. We look forward to 2020 together! %MCEPASTEBIN%

Gedea Biotech today announced that it has received €3 M from the EU program Fast Track to Innovation (FTI), part of Horizon 2020. The grant will fund completion of the clinical trial program and preparation work for market introduction of the company’s antibiotic-free  treatment for vaginal infections. Partners in the…

Gedea is spreading the message from the WHO:s Antibiotic Awareness Week 2019. The world urgently needs to change the way it prescribes and uses antibiotics. Even if new medicines are developed, without behaviour change, antibiotic resistance will remain a major threat. Behaviour changes must also include actions to reduce the spread of…

All patients treated in Swedish women’s health company Gedea Biotech’s pHyph proof of concept study in women with bacterial vaginosisLund, Sweden, October 31, 2019. Gedea Biotech, an innovative women’s health company today reports that all 24 patients have been treated with its lead product, pHyph, a vaginal tablet for topical treatment…

Gedea Biotech will participate in RCOG's World Congress in London, June 17-19. Marketing Manager Eva Norell will participate and she is responsible for Gedea´s market insight: -  We keep up-to-date with both the medical development in vaginal infections and we listen to what doctors and patients really need. A large congress,…

Gedea has received SEK 3 million  Swelife and MedTech4Health. Gedea applied for the grant to verify, in collaboration with Region Skåne, the effect of pHyph in a larger placebo-controlled clinical trial for a market launch in Europe. Swelife and MedTech4Health are part of Vinnova, the Swedish Energy Agency and Forma's…

Women's health is both a health issue and a gender issue. At the International Women's Day, WHO draws attention to important efforts in research and health, for and by women. Health issues have a huge impact on women´s possibilities to patyiciapte in sociaty and working life. Gedea Biotech works for women's…

Gedea Biotech won third prize in the European Final of the EIT European Health Catapult, in the category of Biotech. Gedea also won the Crowd Award! This means that the company is one of Europe's absolute best start-up companies in the health sector. After months of a preparations and competitions,…

Gedea has been granted SEK 500,000 in appropriations from the SME Instrument phase 1 program within the EU Horizon 2020 framework program. The Horizon 2020 program is competitive and only a few percent of all grant applications are granted. - The grant from Horizon 2020 is both an important funding…

Gedea has received approval from the Swedish Medical Products Agency the first clinical studyLast week, the Medical Products Agency and Ethics Committee announced that they approved Gedea's first clinical study. The study is an important step towards CE marking of pHyph, which is a completely new type of treatment of…

Gedea Biotech has reached the final at European Health Catapult, a European startup competition. In tough competition by really strong companies, Gedea went on to the final in Lodz in December. Out of the 14 who reached to the semifinal, seven went on and Gedea is one of them. Another…

Last Wednesday, Gedea Biotech won a shared first place and Akuru Pharma a third, in the pitch competition "Startup Challenge" at NLSDays, the Nordic region's largest partnering fair in life science. It is the second consecutive year that SmiLe companies take top positions in the competition.Read full article here:

Gedea Biotech has reached the finals in Serendipity Challenge that is  an annual entrepreneurship competition and tech venue open to all Swedish and Nordic startups and growth companies. The competition final takes place during Almedalsveckan (2-4 July) where 50 of the most innovative and promising companies compete for the titles. …

Today, Rapidus draws attention to the problem of antimicrobial resistance and the challenge of more and more antibiotics becoming ineffective. Gedea Biotech's forthcoming treatment is mentioned as a solution, among others, which will make us less dependent on antibiotics.Read full article

Smile Company Gedea Biotech has received 1 MSEK  in Vinnova funding in Swelife and MedTech4Health's joint announcement "Project for better health". The money will finance the first clinical trial in patients with vaginal fungal infection.Read more

Three-quarters of all women suffer at some time of fungal infections in the genital area, which gives physical discomfort in the short term but is also likely to cause chronic problems. Now a research team at Lund University have found a naturally occurring substance, which in test tube studies have…

Vinnova has granted Gedea Biotech's application for innovative startup companies. The applications were reviewed by external assessors and Gedea Biotech was one of the selected among over 650 applicants. Gedea Biotech develops a novel treatment of vaginal candida infections. In the project a prototype of the vaginal tablet will be…

Gedea Biotech won first prize at Lund University and Sparbanksstiftelsen Finn's competition for future innovations. The award was presented at Lund University's annual Innovation kickoff. The contest was open to all students and employees at Lund University. 77 entries were received, and a few were selected to pitch in and…

Things goes well for the newly started company Gedea Biotech AB. During the first months of this year, the company, which is still in an early stage, received nearly one million crowns in grants. Now awaits continued development and then clinical studies and the company expects to be able to…

http://www.kemivarldenbiotech.se/nyheter/gedea-biotech-till-final/Gedea Biotech has been selected as one of the shortlisted entrants for the Emerging Technologies Competition, a European competition organized by the Royal Society of Chemistry in collaboration with industrial partners such as AstraZeneca, Pfizer and GE Healthcare. As one of the finalists, Gedea Biotech will present the company at…

Gedea Biotech has been selected as one of the 12 regional finalists in Venture Cup South among close to 400 contributions. Venture Cup is the competition of entrepreneurs of tomorrow, held every year since 1998. The participating teams compete in four categories: Student Superstart, Top Tech, Game Changer and Impact…

Gedea Biotech was on thursday evening crowned as winner of Game Changer award in Venture Cup competition Startup in Malmö. A Game Changer is an innovative startups with Potential to disrupt a current industry and the competitors were the 12 finalists chosen among close to 400 contributions. The prize was…

The magazine Kemivärlden Biotech recently published an article about Gedea Biotech, where chairman Olov Sterner describes the driving force to find a treatment of vaginal infections which is not based on antibiotics to get around the resistance problem. The article also describes the company's current and planned development.Read more

Gedea Biotech is one of 15 finalists in the national Venture cup final in Lund on September 21. The company advanced after winning Southern Sweden's semifinal in the "Game changer" class. Gedea Biotech, which develops an antibiotic-free, local treatment with a completely new mode of action for the treatment of…

Rapidus made a list of talented young professionals in the business environment in Skåne "that Stockholm based media missed". On the list is Annette Säfholm, CEO of Gedea Biotech.Read full article here.

Gedea Biotech has raised 11 MSEK for clinical trials throughout 2018, to verify the treatment of vaginal infections. The share issue has attracted a large interest from investors and was expanded from estimated 7 MSEK to 11 MSEK.Read more

Gedea Biotech has been granted 900.000 SEK in Vinnova's grant program for innovative startup companies. The company has also expanded the board with Mats Persson, who has over 30 years of experience in marketing and sales in life sciences. The recruitment means a valuable strengthening of the board's expertise in…

When the 15 finalists pitched their business ideas, the audience voted to choose their favorite in Thursday's Sweden final in the Venture cup entrepreneurship competition. Gedea Biotech, received the most votes, thereby winning the Venture Cup Crowd Award, and free business trips by train in first class with SJ for…